Journal of Occupational
Health and Epidemiology
Rafsanjan university Of medical sciences
Volume 14, Issue 4 (Autumn 2025)
J Occup Health Epidemiol 2025, 14(4): 240-247 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mohammadi M, Golpayegani A, Doost - Mohammadi F, Majidpour F, Hesari E, Dargahpour M et al . Effectiveness of COVID-19 Vaccination on Disease Severity: A Case-Control Study in Southeast Iran. J Occup Health Epidemiol 2025; 14 (4) :240-247
URL: http://johe.rums.ac.ir/article-1-1079-en.html
URL: http://johe.rums.ac.ir/article-1-1079-en.html
Related article in
Google Scholar
Google Scholar
Similar articles
Mohsen Mohammadi1 
, Abdolali Golpayegani2 , Fatemeh Doost - Mohammadi3 , Fatemeh Majidpour4 , Elahe Hesari5 , Maryam Dargahpour6 , Parisa Jalali *7
, Abdolali Golpayegani2 , Fatemeh Doost - Mohammadi3 , Fatemeh Majidpour4 , Elahe Hesari5 , Maryam Dargahpour6 , Parisa Jalali *7
1- Assistant Prof., Dept. of Epidemiology and Biostatics, School of Public Health, Lorestan University of Medical Sciences, Khorramabad, Iran.
2- Assistant Prof., Dept. of Environmental Health Engineering, School of Public Health, Bam University of Medical Sciences, Bam, Iran.
3- Ph.D. Student in Epidemiology, Clinical Research Development Unit, Shahid Bahonar Hospital, Kerman University of Medical Sciences, Kerman, Iran. & Ph.D. Student in Epidemiology, Dept. of Epidemiology and Biostatistics, School of Public Health, Shahid Sadoughi University of Medical Science, Yazd, Iran.
4- Ph.D Student in Biostatistics, Modeling in Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
5- Ph.D. Student in Epidemiology, Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
6- M.Sc. in Health Management, School of Public Health, Lorestan University of Medical Sciences, Khorramabad, Iran.
7- Ph.D. Student in Epidemiology, Dept. of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Science, Tehran, Iran. ,jalalip24@gmail.com
2- Assistant Prof., Dept. of Environmental Health Engineering, School of Public Health, Bam University of Medical Sciences, Bam, Iran.
3- Ph.D. Student in Epidemiology, Clinical Research Development Unit, Shahid Bahonar Hospital, Kerman University of Medical Sciences, Kerman, Iran. & Ph.D. Student in Epidemiology, Dept. of Epidemiology and Biostatistics, School of Public Health, Shahid Sadoughi University of Medical Science, Yazd, Iran.
4- Ph.D Student in Biostatistics, Modeling in Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
5- Ph.D. Student in Epidemiology, Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
6- M.Sc. in Health Management, School of Public Health, Lorestan University of Medical Sciences, Khorramabad, Iran.
7- Ph.D. Student in Epidemiology, Dept. of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Science, Tehran, Iran. ,
Article history
Received: 2025/07/12
Accepted: 2025/10/19
ePublished: 2025/12/13
Accepted: 2025/10/19
ePublished: 2025/12/13
Subject:
Epidemiology
Abstract: (37 Views)
Background: Given the importance of the effectiveness of vaccination in terms of mitigating the severity of COVID-19 and mortality, knowledge of the effect of the vaccine on the severity of COVID-19 in communities is essential. Thus, the purpose of this study was to ascertain the effect of COVID-19 vaccine on the severity of the COVID-19 in southeastern Iran.
Materials and Methods: A case–control study of a total of 1520 adults aged >18 years was conducted in Bam County to assess the association between hospitalizations due to COVID-19 and previous vaccination with existing vaccines (including Sinopharm, AstraZeneca, and CovIran Barkat) in the country. Multinomial logistic regression was employed, and odds ratios (OR) and 95% confidence intervals (CIs) were calculated.
Results: After controlling for potential confounders, multinomial logistic regression indicated that COVID-19 vaccination lowered the likelihood of hospitalization for men and women in temporary wards (ORmen=0.22 vs ORwomen=0.34), general wards (ORmen=0.25 vs ORwomen=0.31), and intensive care units (ORmen=0.47 vs ORwomen=0.77) (P<0.001). The odds ratio of hospitalization in all wards diminished for men and women who had received Sinopharm or AstraZeneca and for women who had received the Barkat vaccine, while only a significant difference was detected in the reduction among patients who had received the Sinopharm vaccine (P<0.001).
Conclusion: The results revealed that vaccination is related to diminished severity of the disease in the hospital. Thus, efforts to increase the vaccinated population can reduce the severity of COVID-19 and might decreasae the need for intensive care in hospitals.
Materials and Methods: A case–control study of a total of 1520 adults aged >18 years was conducted in Bam County to assess the association between hospitalizations due to COVID-19 and previous vaccination with existing vaccines (including Sinopharm, AstraZeneca, and CovIran Barkat) in the country. Multinomial logistic regression was employed, and odds ratios (OR) and 95% confidence intervals (CIs) were calculated.
Results: After controlling for potential confounders, multinomial logistic regression indicated that COVID-19 vaccination lowered the likelihood of hospitalization for men and women in temporary wards (ORmen=0.22 vs ORwomen=0.34), general wards (ORmen=0.25 vs ORwomen=0.31), and intensive care units (ORmen=0.47 vs ORwomen=0.77) (P<0.001). The odds ratio of hospitalization in all wards diminished for men and women who had received Sinopharm or AstraZeneca and for women who had received the Barkat vaccine, while only a significant difference was detected in the reduction among patients who had received the Sinopharm vaccine (P<0.001).
Conclusion: The results revealed that vaccination is related to diminished severity of the disease in the hospital. Thus, efforts to increase the vaccinated population can reduce the severity of COVID-19 and might decreasae the need for intensive care in hospitals.
Keywords: COVID-19 Vaccines [MeSH], SARS-CoV-2 [MeSH], Hospitalization [MeSH], Vaccine Efficacy [MeSH]
References
1. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427. [DOI] [PMID] [PMCID]
2. Ciotti M, Ciccozzi M, Terrinoni A, Jiang WC, Wang CB, Bernardini S. The COVID-19 pandemic. Crit Rev Clin Lab Sci. 2020;57(6):365-88. [DOI] [PMID]
3. World Health Organization. WHO COVID-19 dashboard. Geneva, Switzerland: World Health Organization; 2023.
4. Wang J, Jing R, Lai X, Zhang H, Lyu Y, Knoll MD, et al. Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China. Vaccines (Basel). 2020;8(3):482. [DOI] [PMID] [PMCID]
5. Sadarangani M, Abu Raya B, Conway JM, Iyaniwura SA, Falcao RC, Colijn C, et al. Importance of COVID-19 vaccine efficacy in older age groups. Vaccine. 2021;39(15):2020-3. [DOI] [PMID] [PMCID]
6. Ellington S, Jatlaoui TC. COVID-19 vaccination is effective at preventing severe illness and complications during pregnancy. Lancet. 2023;401(10375):412-3. [DOI] [PMID] [PMCID]
7. Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al. Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. N Engl J Med. 2021;385(15):1355-71. [DOI] [PMID] [PMCID]
8. Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet. 2022;399(10327):814-23. [DOI] [PMID] [PMCID]
9. Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761-73. [DOI] [PMID] [PMCID]
10. El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021;385(19):1774-85. [DOI] [PMID] [PMCID]
11. Ghiasi N, Valizadeh R, Arabsorkhi M, Hoseyni TS, Esfandiari K, Sadighpour T, et al. Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion. Immunopathol Persa. 2021;7(2):e31. [DOI]
12. Mirahmadizadeh A, Heiran A, Bagheri Lankarani K, Serati M, Habibi M, Eilami O, et al. Effectiveness of COVID-19 Vaccines in preventing Infectiousness, Hospitalization and Mortality: A Historical Cohort Study Using Iranian Registration Data During Vaccination program. MedRxiv. 2022. [DOI]
13. Babamahmoodi F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Mousavi SA, Ovaise G, et al. Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran. Sci Rep. 2021;11(1):21464. [DOI] [PMID] [PMCID]
14. Selvavinayagam TS, Parthipan K, Subramaniam S, Somasundaram A, Sampath P, Kumar V. Role of Covid vaccine in determining ICU admission and death due to Covid-19 in Tamil Nadu. MedRxiv. 2022. [DOI]
15. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021;326(1):35-45. [DOI] [PMID] [PMCID]
16. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-81. [DOI] [PMID] [PMCID]
17. Ridgway JP, Tideman S, French T, Wright B, Parsons G, Diaz G, et al. Odds of Hospitalization for COVID-19 after 3 vs 2 Doses of mRNA COVID-19 Vaccine by Time Since Booster Dose. JAMA. 2022;328(15):1559-61. [DOI] [PMID] [PMCID]
18. Accorsi EK, Britton A, Shang N, Fleming-Dutra KE, Link-Gelles R, Smith ZR, et al. Effectiveness of homologous and heterologous Covid-19 boosters against Omicron. N Engl J Med. 2022;386(25):2433-5. [DOI] [PMID] [PMCID]
19. Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, et al. Effectiveness of COVID-19 booster vaccines against COVID-19–related symptoms, hospitalization and death in England. Nat Med. 2022;28(4):831-7. [DOI] [PMID] [PMCID]
20. Niessen FA, Knol MJ, Hahné SJM; VECTOR study group; Bonten MJM, Bruijning-Verhagen PCJL. Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands: a test-negative case-control study. Vaccine. 2022;40(34):5044-9. [DOI] [PMID] [PMCID]
21. Wenham C, Smith J, Morgan R; Gender and COVID-19 Working Group. COVID-19: the gendered impacts of the outbreak. Lancet. 2020;395(10227):846-8. [DOI] [PMID] [PMCID]
22. Zhang Y, Belayachi J, Yang Y, Fu Q, Rodewald L, Li H, et al. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. BMC Public Health. 2022;22(1):1584. [DOI] [PMID] [PMCID]
23. Wang C, Chen LY, Lu QB, Cui F. Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease. Vaccines (Basel). 2022;10(6):920. [DOI] [PMID] [PMCID]
24. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326(20):2043-54. [DOI] [PMID] [PMCID]
25. Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, et al. The impact of vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. Clin Infect Dis. 2021;73(12):2257-64. [DOI] [PMID] [PMCID]
26. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: a cohort study. Lancet. 2022;399(10332):1303-12. [DOI] [PMID] [PMCID]
27. Stoliaroff Pepin A, Peine C, Herath T, Lachmann J, Hellenbrand W, Perriat D, et al. Vaccine effectiveness against severe COVID 19 during the Omicron wave in Germany: results from the COViK study. Infection. 2023;51(4):1093-102. [DOI] [PMID] [PMCID]
28. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21(10):626-36. [DOI] [PMID] [PMCID]
29. Ioannidis JPA. Factors influencing estimated effectiveness of COVID-19 vaccines in non-randomised studies. BMJ Evid Based Med. 2022;27(6):324-9. [DOI] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution 4.0 International License. |
